Advertisement
Advertisement
CMMB
Chemomab Therapeutics Ltd. - ADR
1.59
USDSponsored
+0.01
+0.64%
Mar 25, 15:50 UTC -4
Closed
Pre-Market
1.60
+0.01
+0.94%
CMMB Earnings Reports
Positive Surprise Ratio
CMMB beat 4 of 21 last estimates.
19%
Next Report
Date of Next Report
May 13, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/-$0.15
Implied change from Q4 25 (Revenue/ EPS)
--
/-37.50%
Implied change from Q1 25 (Revenue/ EPS)
--
/-73.21%
Chemomab Therapeutics Ltd. - ADR earnings per share and revenue
On Mar 19, 2026, CMMB reported earnings of -0.24 USD per share (EPS) for Q4 25, beating the estimate of -0.31 USD, resulting in a 24.10% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -8.52% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.15 USD, with revenue projected to reach -- USD, implying an decrease of -37.50% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
BioCardia, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.06
Surprise
+65.40%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
FAQ
What were Chemomab Therapeutics Ltd. - ADR's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Chemomab Therapeutics Ltd. - ADR reported EPS of -$0.24, beating estimates by 24.1%, and revenue of $0.00, 0% as expectations.
How did the market react to Chemomab Therapeutics Ltd. - ADR's Q4 2025 earnings?
The stock price moved down -8.52%, changed from $1.96 before the earnings release to $1.79 the day after.
When is Chemomab Therapeutics Ltd. - ADR expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Chemomab Therapeutics Ltd. - ADR's next earnings report?
Based on 3
analysts, Chemomab Therapeutics Ltd. - ADR is expected to report EPS of -$0.15 and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement